Skip to main content
Premium Trial:

Request an Annual Quote

Binx Health, Wellfleet Expand Insurance Deal to Cover At-Home, In-Dorm STI Testing for US Students

NEW YORK ─ Boston-based Binx Health will provide access to sexually transmitted infection testing for US college students as part of an expanded agreement with health insurer Wellfleet, the companies announced Wednesday.

The agreement will enable students in US colleges and universities that offer health insurance through Wellfleet to get tested through a Binx at-home and in-dorm digital platform.

Financial and other terms of the expanded agreement were not disclosed.

In October 2020, Binx and Springfield, Massachusetts-based Wellfleet, a Berkshire Hathaway company, had announced an agreement that enabled college students to do at-home and in-dorm sample collection for COVID-19 testing using Binx's enterprise solutions for population health screening.

In March, the US Food and Drug Administration granted a CLIA waiver to Binx for its io CT/NG Assay, which runs on the firm's PCR-based io instrument and detects and distinguishes Chlamydia trachomatis and Neisseria gonorrhoeae in approximately 30 minutes using either female vaginal swab or male urine specimens.

In February, Binx announced a partnership with McKesson for the sale and distribution of the Binx io testing platform in the US.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.